Current Report Filing (8-k)
October 12 2021 - 7:26AM
Edgar (US Regulatory)
0001359931
false
0001359931
2021-10-12
2021-10-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 12, 2021
Protara
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36694
|
|
20-4580525
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer
Identification No.)
|
345
Park Avenue South
Third
Floor
New
York, NY
|
|
10010
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (646) 844-0337
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
TARA
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation FD Disclosure.
On
October 12, 2021, Protara Therapeutics, Inc. (the “Company”) issued a press release entitled “Protara Therapeutics
Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer,”
a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
The
information in this Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed”
for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall the information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended
or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any
such filing.
Item
8.01. Other Events.
On
October 12, 2021, the Company made available a Corporate Presentation on the Investor Relations page of the Company’s website,
which will be used at investor and other meetings. A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current
Report on Form 8-K and is incorporated herein by reference. The Company does not undertake to update this presentation.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
PROTARA
THERAPEUTICS, INC.
|
|
|
|
Date:
October 12, 2021
|
By:
|
/s/
Blaine Davis
|
|
|
Blaine
Davis
|
|
|
Chief
Financial Officer
|
3
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024